MATCHING BRCA AND PROSTATE CANCER IN A PUBLIC HEALTH SYSTEM: REPORT OF THE ITALIAN SOCIETY FOR URO-ONCOLOGY (SIUrO) CONSENSUS PROJECT.

The recent approval of PARP inhibitors for the treatment of metastatic castration-resistant prostate cancer (mCRPC) patients with BRCA mutations firstly introduced the possibility of proposing a targeted treatment in this disease. However, the availability of this therapeutic option raises a number of questions concerning the management of prostate cancer in everyday clinical practice: the timing and method of detecting BRCA mutations, the therapeutic implications of the detection, and the screening of the members of the family of a prostate cancer patient with a BRCA alteration. These challenging issues led the Italian Society for Uro-Oncology (SIUrO) to organise a Consensus Conference aimed to develop suggestions capable of supporting clinicians managing prostate cancer patients. The present paper described the development of the statements discussed during the consensus, which involved all of the most important Italian scientific societies engaged in the multi-disciplinary and multi-professional management of the disease.

• Publication year

  2023

• Venue

  Critical reviews in oncology/hematology

• Publication date

  2023-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.critrevonc.2023.103959PMID 36921782
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Economic value of knowing BRCA status: BRCA testing for prostate cancer prevention and optimal treatment

  2023cited by this paper
• TALAPRO-2: Phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) versus placebo (PBO) + ENZA as first-line (1L) treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

  2023cited by this paper
• Tumor Genomic Testing for >4000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib).

  2022cited by this paper
• Cancer statistics, 2022

  2022cited by this paper
• Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer.

  2022cited by this paper
• Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer: a position paper of Italian Scientific Societies

  2022cited by this paper
• Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021.

  2022cited by this paper
• Controlling the Control Arm in Metastatic Castration-Resistant Prostate Cancer Trials: Best Standard of Care or the Minimum Standard of Care?

  2022cited by this paper
• Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial.

  2022cited by this paper
• Differential Activity of PARP Inhibitors in BRCA1- Versus BRCA2-Altered Metastatic Castration-Resistant Prostate Cancer

  2021cited by this paper
• Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial.

  2021cited by this paper
• BRCA Germline Mutations in Prostate Cancer: The Future Is Tailored

  2021cited by this paper
• Olaparib efficacy in patients with metastatic castration-resistant prostate cancer (mCRPC) carrying circulating tumor (ct) DNA alterations in BRCA1, BRCA2 or ATM: Results from the PROfound study.

  2021cited by this paper
• Genomic Analysis of Circulating Tumor DNA in 3,334 Patients with Advanced Prostate Cancer Identifies Targetable BRCA Alterations and AR Resistance Mechanisms

  2021cited by this paper
• Cost-Effectiveness of Genomic Test-Directed Olaparib for Metastatic Castration-Resistant Prostate Cancer

  2021cited by this paper
• EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent.

  2020cited by this paper
• EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II-2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer.

  2020cited by this paper
• Activity of Platinum-Based Chemotherapy in Patients With Advanced Prostate Cancer With and Without DNA Repair Gene Aberrations

  2020cited by this paper
• The kinase polypharmacology landscape of clinical PARP inhibitors

  2020cited by this paper
• Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study

  2020cited by this paper
• Olaparib for Metastatic Castration-Resistant Prostate Cancer.

  2020cited by this paper
• Similar response rates and survival with PARP inhibitors for patients with solid tumors harboring somatic versus Germline BRCA mutations: a Meta-analysis and systematic review

  2020cited by this paper
• Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer.

  2020cited by this paper
• Impact of DNA damage repair defects and aggressive variant features on response to carboplatin‐based chemotherapy in metastatic castration‐resistant prostate cancer

  2020cited by this paper
• Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration

  2020cited by this paper
• Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers

  2019cited by this paper
• Genomic Analysis of Three Metastatic Prostate Cancer Patients with Exceptional Responses to Carboplatin Indicating Different Types of DNA Repair Deficiency

  2019cited by this paper
• Multifocal Primary Prostate Cancer Exhibits High Degree of Genomic Heterogeneity.

  2019cited by this paper
• Genomics of lethal prostate cancer at diagnosis and castration resistance

  2019cited by this paper
• Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial

  2019cited by this paper
• Towards controlled terminology for reporting germline cancer susceptibility variants: an ENIGMA report

  2019cited by this paper
• PARP inhibitors: clinical development, emerging differences, and the current therapeutic issues

  2019cited by this paper
• Tumour lineage shapes BRCA-mediated phenotypes

  2019cited by this paper
• Epidemiology of Prostate Cancer

  2019cited by this paper
• Moving From Poly (ADP-Ribose) Polymerase Inhibition to Targeting DNA Repair and DNA Damage Response in Cancer Therapy.

  2019cited by this paper
• Bone biopsy protocol for advanced prostate cancer in the era of precision medicine

  2018cited by this paper
• Estrogen receptor signaling in prostate cancer: Implications for carcinogenesis and tumor progression

  2018cited by this paper
• Genetic testing for hereditary prostate cancer: Current status and limitations

  2018cited by this paper
• The evolving landscape of predictive biomarkers of response to PARP inhibitors.

  2018cited by this paper
• The long tail of oncogenic drivers in prostate cancer

  2018cited by this paper
• Estrogens and Their Receptors in Prostate Cancer: Therapeutic Implications

  2018cited by this paper
• The association between germline BRCA2 variants and sensitivity to platinum‐based chemotherapy among men with metastatic prostate cancer

  2017cited by this paper
• Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance

  2017cited by this paper
• Guidance Statement On BRCA1/2 Tumor Testing in Ovarian Cancer Patients.

  2017cited by this paper
• Anti-tumour activity of platinum compounds in advanced prostate cancer-a systematic literature review.

  2016cited by this paper
• Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer.

  2016cited by this paper
• Biallelic Inactivation of BRCA2 in Platinum-sensitive Metastatic Castration-resistant Prostate Cancer.

  2016cited by this paper
• Prostate cancer stem cells: the role of androgen and estrogen receptors

  2015cited by this paper
• The Molecular Taxonomy of Primary Prostate Cancer.

  2015cited by this paper
• Analysis of Pre-Analytic Factors Affecting the Success of Clinical Next-Generation Sequencing of Solid Organ Malignancies

  2015cited by this paper
• Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian

  2015cited by this paper
• DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.

  2015cited by this paper
• Mersch J, Jackson MA, Park M, Nebgen D, Peterson SK, Singletary C, Arun BK and Litton JK. Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian. Cancer. 2015;121:269‐275.

  2015cited by this paper
• Integrative clinical genomics of advanced prostate cancer.

  2015cited by this paper
• KBG Syndrome: A Case Report and Longitudinal Assessment of Long‐Acting Recombinant Human Growth Hormone Therapy

  2015cited by this paper
• Effect of BRCA Mutations on Metastatic Relapse and Cause-specific Survival After Radical Treatment for Localised Prostate Cancer.

  2015cited by this paper
• Cisplatin in cancer therapy: molecular mechanisms of action.

  2014cited by this paper
• A practice guideline from the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors: referral indications for cancer predisposition assessment

  2014cited by this paper
• Distribution of metastatic sites in patients with prostate cancer: A population‐based analysis

  2014cited by this paper
• Prostate cancer in young men: an important clinical entity

  2014cited by this paper
• Exploring the application of the Delphi method as a forecasting tool in Information Systems and Technologies research

  2014cited by this paper
• DNA Qualification Workflow for Next Generation Sequencing of Histopathological Samples

  2013cited by this paper
• Successful whole-exome sequencing from a prostate cancer bone metastasis biopsy

  2013cited by this paper
• Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer.

  2013cited by this paper
• Androgen receptor signaling regulates DNA repair in prostate cancers.

  2013cited by this paper
• Archived Formalin-Fixed Paraffin-Embedded (FFPE) Blocks: A Valuable Underexploited Resource for Extraction of DNA, RNA, and Protein

  2013cited by this paper
• Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors.

  2012cited by this paper
• Germline BRCA1 mutations increase prostate cancer risk

  2012cited by this paper
• Early onset prostate cancer has a significant genetic component

  2012cited by this paper
• BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients

  2011cited by this paper
• Germline BRCA Mutations Denote a Clinicopathologic Subset of Prostate Cancer

  2010cited by this paper
• Assessing pathogenicity: overview of results from the IARC Unclassified Genetic Variants Working Group

  2008cited by this paper
• The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma

  2005cited by this paper
• Genotype-phenotype analysis of the Crohn’s disease susceptibility haplotype on chromosome 5q31

  2003cited by this paper
• Cancer Incidence in BRCA1 mutation carriers.

  2002cited by this paper
• Review Cancer Susceptibility and the Functions of BRCA1 and BRCA2

  2002cited by this paper
• Cancer susceptibility and the functions of BRCA1 and BRCA2.

  2002cited by this paper
• Expert Opinions in Forecasting: The Role of the Delphi Technique

  2001cited by this paper
• Cancer risks in BRCA2 mutation carriers.

  1999cited by this paper
• BRCA1 inhibition of estrogen receptor signaling in transfected cells.

  1999cited by this paper
• Biological aggressiveness of hereditary prostate cancer: long-term evaluation following radical prostatectomy.

  1998cited by this paper
• Identification of the breast cancer susceptibility gene BRCA2

  1995cited by this paper
• Qualitative Research: Consensus methods for medical and health services research

  1995cited by this paper
• A large kindred with 17q-linked breast and ovarian cancer: genetic, phenotypic, and genealogical analysis.

  1994cited by this paper
• A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1.

  1994cited by this paper
• Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13.

  1994cited by this paper
• Mendelian inheritance of familial prostate cancer.

  1992cited by this paper
• A comparative study of differences in subjective likelihood estimates made by individuals, interacting groups, Delphi groups, and nominal groups☆

  1973cited by this paper

• Integrating BRCA testing into routine prostate cancer care: a multidisciplinary approach by SIUrO and other Italian Scientific Societies

  2025cites this paper
• Internal Overview of Prostatic Cancer Cases and Quality of BRCA1 and BRCA2 NGS Data from the FFPE Tissue

  2024cites this paper